What Genomics Biosci & Tech Co does

Genomics Biosci & Tech Co (基龍米克斯, ticker 4195.TWO) is Taiwan's largest commercial genomic services company, operating a full-stack sequencing platform spanning first-generation (Sanger), second-generation (Illumina NovaSeq X Plus, first installation in Taiwan), and third-generation (PacBio) technologies, alongside proprietary self-built production lines. The company runs Taiwan's largest genomic core laboratory out of its New Taipei City headquarters, with regional sales offices in Taichung, Tainan, and Kaohsiung, and a planned U.S. subsidiary in Boston. It holds multiple first-in-Taiwan regulatory milestones: TAF ISO/IEC 17025:2017 certification for sequencing, Taiwan's first PIC/S GMP-certified nucleic acid and peptide synthesis plant (co-built with ITRI), TFDA LDTs registration, and proficiency-test passes from CAP, INSTAND, and EMQN.

The business operates three integrated revenue streams. The core research-services line delivers sequencing, oligonucleotide/RNA/gene/peptide synthesis, genomic and proteomic (Olink PEA) services to academic, government, and biotech clients (2,200+ cumulative customers including Taiwan Biobank and Cancer Moonshot). The clinical-testing line runs certified reproductive-health and oncology panels (NIPT, 癌精準523, 癌必立523, 安可癒, 安護妳) into hospitals and medical centers. A higher-growth CDMO line, anchored by the PIC/S GMP plant, contracts nucleic acid adjuvant and TIDES manufacturing for vaccine and cell/gene-therapy customers at gram-scale (CpG7909, CpG1018). Distribution revenue from exclusive agencies for Thermo Fisher Scientific LPD, Applied Biosystems SeqStudio, QIAGEN, Olink, PacBio, and Clean Station provides a recurring consumables tail. The company went public on the Taiwan OTC Innovation Board in May 2024 and reported record FY2025 consolidated revenue of NT$708 million (≈US$22 million); its wholly-owned subsidiary Lester Biomedical (spun off July 2026 with Mosaic Venture Lab and Taiwan National Development Fund backing) extends the model into AI-driven drug discovery for drug-resistant infections and Parkinson's disease.

Name

Genomics Biosci & Tech Co

Legal name

Genomics BioSci & Tech Co., Ltd. (基龍米克斯生物科技股份有限公司)

Website

https://genomics.com.tw

Company type

Public

Founded year

2009

Operating status

Operating

Short description

Genomics Biosci & Tech (4195.TWO) is Taiwan's largest commercial genomic services company, providing sequencing (Sanger, Illumina NovaSeq X Plus, PacBio), clinical genetic testing, and PIC/S GMP CDMO for nucleic acid adjuvants and peptides to hospitals, research institutions, biotech firms, and vaccine manufacturers.

Ownership category

akta.pro rank

Product category

Genomic Sequencing Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industry

mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)

Keywords

• Genomic sequencing services
• Clinical genetic testing
• Nucleic acid synthesis
• CDMO manufacturing services
• Proteomics analysis

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure

Revenue model

1. Research Services: Revenue from sequencing services (Sanger, NGS, PacBio), synthesis services (Oligo, RNA, gene, peptide synthesis), genomic services, proteomic services, and agency/distribution of equipment and reagents from brands such as Thermo Fisher Scientific, QIAGEN, and Applied Biosystems. This is the core revenue stream, covering scientific research institutions and universities.
2. Clinical Testing Services: Revenue from clinical genetic testing including reproductive health (NIPT, SMA, Fragile X), cancer testing (癌精準523, 癌必立523, 安可癒, 安護妳), and LDTs-certified tests. Delivered to hospitals, medical centers, and directly to patients through physicians.
3. CDMO (Contract Development and Manufacturing): Revenue from contract manufacturing of nucleic acid adjuvants, oligonucleotides, and peptides under PIC/S GMP conditions. Targets vaccine manufacturers and cell/gene therapy companies. Expected to begin commercial production and contribute to revenues following GMP inspection and approval.
4. Agency & Distribution (Products & Consumables): Revenue from distribution and resale of laboratory instruments and consumables including Thermo Fisher Scientific LPD series products (cold storage, biosafety cabinets, CO2 incubators), Applied Biosystems SeqStudio Genetic Analyzer, Clean Station air purification, and other brands.

Pricing tiers

Go-to-market motion4 records

Distribution channels6 records

Marketing channels7 records

Core offering

Genomics Biosci & Tech Co is Taiwan's largest commercial genomic services company, providing one-stop genomic services spanning first-, second-, and third-generation DNA sequencing (Sanger, Illumina NovaSeq X Plus, PacBio), oligo/RNA/gene/peptide synthesis, clinical genetic testing (NIPT, cancer panels, hereditary disease screening), Olink proteomics, and PIC/S GMP-certified contract development and manufacturing (CDMO) of nucleic acid adjuvants and peptides for vaccine and cell/gene therapy customers.

Differentiator

Problem solved

Functional benefit

Brands

• Genomart: Online shopping platform for Genomics products and services
• 萊斯特生醫 (Lester Biomedical)
• 康斯達精密 (Consta Precision)
• Anti-biotics 3.0

Products and services

• Sequencing Services
• Synthesis Services
• Genomic Services

Quantifiable outcome

• Reduced gross margin loss — gross margin improved from 28% in 2021 to 32% in 2022 due to upgraded laboratory equipment and process optimization
• +5 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature10 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Thermo Fisher ScientificcoreChannel Partner/ Reseller/ Distributor · 13 March 2024Genomics signed an exclusive sales agency contract for Thermo Fisher Scientific's Laboratory Product Division (LPD) products in Taiwan. This includes low-temperature and ultra-low temperature refrigerators, biosafety cabinets, CO2 incubators, and clean benches. Additionally, Genomics holds exclusive distribution rights for Applied Biosystems SeqStudio Genetic Analyzer in Taiwan's hospital channels. The partnership builds on a 2021 exclusive agency for animal health testing reagents.
• Wyzer Biosciences Inc.coreStrategic or Co-development Partner · 18 July 2023Genomics acquired a 16% equity stake (139.68 shares) in Wyzer Biosciences Inc., a U.S.-based full-service genetic sequencing company headquartered in Boston, for US$2.88 million (NT$89.28 million). The stake was acquired through a combination of 40% cash payment (US$1.152 million) and 60% stock exchange (2,338,000 new Genomics shares). Wyzer provides Sanger sequencing, NGS, and DNA sample processing services, and serves as Genomics' strategic platform for entering the U.S. market and the Boston biotech ecosystem.
• Illumina Inc.coreTechnology or Integration · 1 January 2023Genomics is Taiwan's first customer to install the Illumina NovaSeq X Plus, the latest highest-throughput NGS platform. This partnership enables Genomics to offer the most advanced second-generation sequencing services in Taiwan, with up to 3TB data output per run, supporting large-scale projects in genomics, cancer research, and precision medicine.
• QIAGENminorChannel Partner/ Reseller/ Distributor · 1 January 2023Genomics represents QIAGEN as a distributor in Taiwan, offering QIAGEN's sample preparation and assay technology products including reagents, laboratory consumables, and automated workstations for molecular biology applications.
• Industrial Technology Research Institute (ITRI)coreStrategic or Co-development Partner · 1 January 2021Genomics partnered with ITRI in 2021 to establish Taiwan's first PIC/S GMP-compliant nucleic acid and peptide synthesis plant. ITRI provided technological guidance and support in building the GMP-certified manufacturing facility, enabling Genomics to enter the TIDES CDMO sector and achieve gram-scale production of CpG7909 and CpG1018 nucleic acid vaccine adjuvants.
• Olink ProteomicscoreTechnology or Integration · 1 January 2021Genomics introduced Olink Proteomics testing services in 2021, utilizing Olink's proprietary Proximity Extension Assay (PEA) technology for high-throughput, multi-protein biomarker detection. Genomics serves as the Taiwan channel partner for Olink's proteomics platform, enabling multiomics research integration with its existing NGS services.

Scale indicators13 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• Macrogen: Macrogen is a Korea-based genomic sequencing and molecular diagnostics service provider offering Sanger, NGS, and clinical genetic testing — closely analogous to Genomics' sequencing services, clinical testing, and laboratory services business across academic, hospital, and biotech customers.
• Personalis: Personalis is a clinical NGS and molecular diagnostics company focused on oncology genomics and comprehensive genomic profiling — directly comparable to Genomics' cancer testing panels (523 cancer-related genes with TMB/MSI) and LDTs-certified clinical NGS offerings.
• Aldevron: Aldevron is a nucleic acid and protein CDMO serving vaccine and gene-therapy developers, including CpG adjuvant manufacturing; the most direct CDMO counterpart to Genomics' PIC/S GMP nucleic acid/peptide adjuvant and TIDES manufacturing franchise.
• Novogene: Novogene is one of Asia's largest sequencing service providers, operating Illumina, PacBio, and Sanger platforms and serving research, clinical, and pharma customers; directly comparable to Genomics' multi-platform sequencing service franchise and CDMO-adjacent offerings.
• NeoGenomics: NeoGenomics is a US oncology-focused clinical laboratory and molecular diagnostics company providing NGS panels and biomarker testing; comparable to Genomics' hospital-facing cancer genetic testing and LDTs-certified clinical diagnostics offerings.
• Twist Bioscience: Twist Bioscience is a leading DNA synthesis and synthetic biology provider with NGS-grade products, comparable in technology and customer base to Genomics' oligo, gene, and probe synthesis services for research customers.
• Yourgene Health: Yourgene Health is a UK-based molecular diagnostics company specializing in NIPT, reproductive health, and clinical genetics with its own proprietary algorithms; a direct peer to Genomics' reproductive health and NIPT business using the proprietary GWNS algorithm.
• GenScript Biotech: GenScript operates gene synthesis, oligonucleotide, peptide, and CDMO services globally, mirroring Genomics' combination of research synthesis services (oligos, probes, RNA, peptide synthesis) and emerging nucleic-acid CDMO business.

Broad incumbents

• BGI Group: BGI is the world's largest genomic sequencing services and clinical testing company, with broad operations across research services, NIPT, and molecular diagnostics; a much larger incumbent that competes with Genomics' clinical genetic testing and sequencing service offerings especially across Asia.
• Eurofins Scientific: Eurofins is a global clinical diagnostics and genomic testing platform with extensive laboratory certification footprints; comparable as a broad incumbent in medical laboratory services, regulatory certifications (ISO 17025), and clinical genetic testing that Genomics also competes in.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/GemomicsHealth

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genomics Biosci & Tech Co